Precision BioSciences, Inc. (DTIL) Stock

Precision BioSciences, Inc., headquartered in Durham, North Carolina, is a pioneering clinical stage gene editing company specializing in the development of in vivo gene editing and ex vivo allogeneic CAR T therapies. Central to its innovation is the ARCUS genome editing platform, designed to address genetic disorders by precisely modifying DNA. This platform holds potential across a spectrum of applications in healthcare, offering promising avenues for therapeutic advancements.

The company's portfolio includes ex vivo Allogeneic CAR T Immunotherapy, a cutting-edge form of immunotherapy where T cells are genetically engineered outside the body to recognize and destroy cancer cells upon reinfusion. Precision BioSciences is advancing several CAR T candidates through clinical trials, including PBCAR0191 for adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL) or B-cell precursor acute lymphoblastic leukemia (B-ALL). Additionally, PBCAR19B and PBCAR269A target specific antigens to treat hematological malignancies like multiple myeloma, demonstrating the company's commitment to addressing critical unmet medical needs.

Established in 2006, Precision BioSciences has forged strategic partnerships to expand its capabilities and accelerate therapeutic development. Collaborations with Les Laboratoires Servier for the development of allogeneic CAR T cell therapies, Tiziana Life Sciences for evaluating foralumab as a potential cancer treatment, and iECURE, Inc. for ARCUS-based gene editing therapies underscore its collaborative approach to advancing precision medicine. With its pioneering technologies and strategic alliances, Precision BioSciences is at the forefront of transforming the landscape of genetic medicine and improving patient outcomes worldwide.